Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective upped by research analysts at Citizens Jmp from $167.00 to $176.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 89.80% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, January 22nd. Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. UBS Group reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $150.00 price target on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $133.71.

Rhythm Pharmaceuticals Trading Down 5.4%

Shares of NASDAQ:RYTM opened at $92.73 on Friday. The stock has a 50 day moving average of $103.90 and a 200 day moving average of $103.54. The company has a market cap of $6.19 billion, a PE ratio of -29.82 and a beta of 2.00. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.06. The business had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 378.31%. The company’s revenue for the quarter was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.72) earnings per share. Equities research analysts predict that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Transactions at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the sale, the insider directly owned 20,814 shares in the company, valued at approximately $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 25,003 shares of company stock worth $2,589,015 over the last quarter. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RYTM. Invesco Ltd. raised its stake in Rhythm Pharmaceuticals by 102.8% during the fourth quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock valued at $31,165,000 after purchasing an additional 147,595 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Rhythm Pharmaceuticals by 94.1% in the 4th quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock worth $446,000 after buying an additional 2,019 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter worth about $1,117,000. Wellington Management Group LLP raised its position in shares of Rhythm Pharmaceuticals by 922.0% during the 4th quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock valued at $26,777,000 after buying an additional 225,679 shares in the last quarter. Finally, SummitTX Capital L.P. raised its position in shares of Rhythm Pharmaceuticals by 580.2% during the 4th quarter. SummitTX Capital L.P. now owns 80,729 shares of the company’s stock valued at $8,641,000 after buying an additional 68,860 shares in the last quarter.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat estimates: EPS of $-0.73 vs. consensus of $-0.79 and revenue of $57.25M (y/y revenue +36.9%). The beat supports commercial traction for IMCIVREE. Zacks: Rhythm Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst upgrade/target raise: Citizens JMP raised its price target to $176 and kept a “market outperform” rating, signaling strong upside to Street models. Benzinga: Citizens JMP raises PT
• Positive Sentiment: Analyst raise: Guggenheim lifted its target to $143 and maintained a “buy” rating, adding another constructive analyst signal. Benzinga: Guggenheim raises PT
• Positive Sentiment: Near‑term clinical/regulatory catalysts remain: PDUFA goal date for the sNDA in acquired hypothalamic obesity on March 20, plus March topline readouts from Phase 3 programs (EMANATE and a Japanese cohort) that could significantly re‑rate the story. GlobeNewswire: Rhythm Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst trim but still constructive: Wells Fargo cut its target to $136 but kept an “overweight” rating, signaling continued confidence despite a smaller upside. Benzinga: Wells Fargo lowers PT
• Neutral Sentiment: Needham lowered its target to $139 but maintained a “buy”—another sign that sell‑side views remain broadly positive even as models are adjusted. TickerReport: Needham lowers PT
• Negative Sentiment: Large near‑term spending guide: Rhythm told investors it expects $385M–$415M in 2026 non‑GAAP operating expenses as hypothalamic‑obesity (HO) launch preparations accelerate — higher burn that may pressure margins and cash runway in the near term. Seeking Alpha: Rhythm anticipates $385M–$415M in 2026 non‑GAAP operating expenses

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.